| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Product revenue, net | 98 | 120 | 168 | 214 |
| Cost of goods sold | 11 | 107 | 14 | 1,170 |
| Research and development | 8,740 | 10,256 | 4,554 | 5,101 |
| Selling, general and administrative | 5,381 | 5,609 | 5,699 | 7,683 |
| Restructuring costs | 194 | 0 | - | 1,553 |
| Total operating expenses | 14,326 | 15,972 | 10,267 | 15,507 |
| Loss from operations | -14,228 | -15,852 | -10,099 | -15,293 |
| Interest expense | 4,373 | 4,222 | 3,993 | 3,790 |
| Interest income | 236 | 230 | 279 | 616 |
| Other (income) expense, net | -12,546 | 657 | 6,559 | 4,817 |
| Net loss | -30,911 | -19,187 | -7,254 | -13,650 |
| Earnings per share, basic | -2.18 | -2.45 | -1.5 | -0.32 |
| Earnings per share, diluted | -2.18 | -2.45 | -1.5 | -0.32 |
| Weighted average number of shares outstanding, basic | 14,196,000 | 7,843,000 | 4,834,000 | 42,390,000 |
| Weighted average number of shares outstanding, diluted | 14,196,000 | 7,843,000 | 4,834,000 | 42,390,000 |
BioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc. (BTAI)